

Symposium at FSGO 2026 Annual Meeting
Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian
Cancer: From Biology to Bedside
June 12, 2026
Longboat Key, FL

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
Planning Disclosures				
Herzog, MD	Thomas	Moderator	Aadi BioScience; AbbVie; AstraZeneca; Caris; Corcept; DSI; Eisai; Epsilon; Genmab; GSK; Merck; Mersana; Natera; Pfizer; Pharma&; PMV Pharma; Sutro; Tempus; Zentalis	Scientific Advisory Board (Aadi BioScience; AbbVie; AstraZeneca; Caris; Corcept; DSI; Eisai; Epsilon; Genmab; GSK; Merck; Mersana; Natera; Pfizer; Pharma&; PMV Pharma; Sutro; Tempus; Zentalis Honorarium (Aadi; Corcept; Merck; Natera)
Speaker Disclosures				
Arend, MD	Rebecca	Speaker	AstraZeneca; Merck; Sharp; Dohme;	Leadership/Advisory (AstraZeneca) Consultant (Merck; Sharp; Dohme)
Naumann, MD	R. Wendel	Speaker	Amgen; Johnson & Johnson; MedTech; Merck Sharp & Dohme; AstraZeneca; Eisai; Bristol-Meyers Squibb; Seagen; Agenus; SturoBio; GOG Partners; GSK/Tesaro; Genelux; Laekna; Immunogen; EMD Serono; Virtual Incision; Incyclix Bio; Genmab/Seattle Genetics; Nimbus; Aadi Bioscience; AbbVie; Incyte; Gilead Sciences; Tubulis GmbH; Tract Bio; Seagen; OncoMed; Sutro-Bio; GOG; Mersana; Schrodinger	Stock/Other Ownership Interests (Amgen) Honoraria (Johnson & Johnson; MedTech) Consulting or Advisory Role (Merck Sharp & Dohme; AstraZeneca; Eisai; Bristol-Myers Squibb; Seagen; Agenus; SturoBio; GOG Partners; GSK/Tesaro; Genelux; Laekna; Immunogen; EMD Serono; Virtual Incision; Incyclix Bio; Genmab/Seattle Genetics; Nimbus; Aadi Bioscience; AbbVie; Incyte; Gilead Sciences; Tubulis GmbH; Tract Bio) Speakers' Bureau (Seagen)

FACULTY DISCLOSURE INFORMATION

				Research Funding (Bristol-Myers Squibb; OncoMed; Sutro-Bio; GOG; Mersana; GSK/Tesaro; Schrodinger)
Engbert	Holley	Staff	Nothing to disclose	
Rush	Heather	Staff	Nothing to disclose	
Shumaker	Kara	Reviewer/Staff	Nothing to disclose	
Small, MPH	Michelle N	Reviewer/Staff	Nothing to disclose	
Alvarez Secord, MD	Angeles	Reviewer/Edu-Chair	AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis; Foundation Medicine; Gilead; Histosonics; Medtronic; Porject Nana; Up to Date; SGO; FWC; GOG Foundation; Amgen; Johnson & Johnson	Research funds to Institution (AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis) Honorarium (Merck; GSK) Advisory Board with Honoraria (AbbVie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; GSK; Genmab; Gilead; Histosonics; Medtronic; Merck) Medical Advisory Board (Porject Nana) Steering Committee Uncomp. (Oncoquest; Genmab) Royalties (Up to Date) Board of Directors (SGO; FWC; GOG Foundation) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	Edu-Co-Chair/Reviewer	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Blank, MD	Stephanie	Reviewer	American Board of Obstetrics and Gynecology; Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.	Leadership (American Board of Obstetrics and Gynecology) Research Funding (Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.)
Gien, MD	Lilian	Reviewer	Glaxo Smith Kline; Merck; Abbvie; AstraZeneca	Speaker Honoraria (Glaxo Smith Kline; Merck) Advisory Board (Abbvie; AstraZeneca)
Mutch, MD	David	Reviewer	Nothing to disclose	
Zwezig, MD	Susan	Reviewer	Nothing to disclose	